BioRexis Pharmaceutical Corporation

BioRexis has developed a proprietary protein engineering technology based on human transferrin, which provides novel therapeutics with longer durations of action compared to synthetic peptides. In addition to reducing the frequency of administration, these technologies have the potential to significantly improve patient tolerance. This new platform supports Pfizer's commitment to developing novel protein therapeutics.